NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN
Antithrombotic treatment of acute coronary syndrome leads to much better outcomes of the disease. The article focuses on the arguments and evidence for the addition to antiplatelet drugs the rivaroxaban 2,5 mg two times per day for secondary prevention of AMI.
Saved in:
Main Authors: | I. N. Bokarev, A. V. Golub |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2015-07-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/234 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
APPLICATION OF RIVAROXABAN IN ACUTE CORONARY SYNDROME: EVIDENCE AND CURRENT GUIDELINES
by: O. V. Averkov
Published: (2016-01-01) -
ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01) -
Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome
by: R. M. Velieva, et al.
Published: (2020-12-01) -
Modern Approaches to Optimal Antithrombotic Therapy for Stable Ischemic Heart Disease
by: G. E. Roytberg, et al.
Published: (2020-10-01) -
Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients
by: T. S. Golovina, et al.
Published: (2020-09-01)